This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Henry, S. P. Articles by Levin, A. A. Search for Related Content PubMed PubMed Citation Articles by Henry, S. P. Articles by Levin, A. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Correlation of Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide Designed to Inhibit ICAM-1

Isis Pharmaceuticals, Inc., Carlsbad, California 92008, shenry{at}isisph.com.

Michael V. Templin

Isis Pharmaceuticals, Inc., Carlsbad, California 92008

Nancy Gillett

Sierra Biomedical, Sparks, Nevada 89431

Jennifer Rojko

Pathology Associates, Inc., Frederick, Maryland 21701

Arthur A. Levin

Isis Pharmaceuticals, Inc., Carlsbad, California 92008

ISIS 2302 is a phosphorothioate oligodeoxynucleotide with a sequence complementary to the mRNA of human intercellular adhesion molecule 1 (ICAM-1). Hybridization of ISIS 2302 to the mRNA inhibits expression of the ICAM-1 protein in response to inflammatory stimuli. A murine active antisense oligonucleotide, ISIS 3082, has been used for in vivo pharmacology studies and has anti-inflammatory activity in models of organ transplant rejection, ulcerative colitis, and collagen-induced arthritis at doses ranging from 0.03 to 5 mg/kg. The safety assessment for ISIS 2302 includes general toxicity studies up to 6 mo in duration in mice and monkeys, genetic toxicity studies, and reproductive/fertility studies. ISIS 3082 was examined in parallel with ISIS 2302 in mouse toxicity and reproductive studies. The toxicities observed following systemic administration of ISIS 2302 and ISIS 3082 were similar and consistent with those observed for other compounds in this chemical class and, therefore, are independent of the suppression of ICAM-1 expression. Toxicokinetic evaluation demonstrated that toxicities occurred in organs containing the highest concentrations of ISIS 2302. Evidence of immune stimulation, including dose-dependent splenomegaly, lymphoid hyperplasia, and multiorgan mixed mononuclear cell infiltrates, was the most common finding in rodent studies. Monkeys were much less sensitive than mice to immune stimulation. Kidney contained the highest concentrations of ISIS 2302. Morphologic changes observed in kidney included atrophic and regenerative changes in proximal tubular epithelium; however, there was no evidence of functional abnormalities. Additional histologic changes noted in proximal tubular epithelium included basophilic granules, which were reflective of oligonucleotide distribution and uptake in these cells. Liver also contained high concentrations of oligonucleotide, which were associated with Kupffer cell hypertrophy in mice. Changes in serum transaminases, cholesterol, and triglycerides were reflective of hepatic alterations. In monkeys, high concentrations of oligonucleotide caused a transient increase in clotting times and activation of the alternative complement pathway. All toxicities associated with ISIS 2302 were reversible and occurred at doses well above those required for pharmacologic activity or currently used in clinical trials. In addition, there has been no evidence of genetic toxicity associated with ISIS 2302, and no changes in reproductive performance, fertility, or fetal development have been noted in animals treated with ISIS 2302 or ISIS 3082.

Key Words: Toxicity • pharmacokinetics • antisense • oligonucleotide • phosphorothioate • intercellular adhesion molecule 1 (ICAM-1)

References

• Agrawal S., Temsamani J., Galbraith W., and Tang J. (1995). Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28: 7-16.[Web of Science][Medline] [Order article via Infotrieve]
• Agrawal S., Temsamani J., and Tang JY (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88: 7595-7599.[Abstract/Free Full Text]
• Bennett CF (1993). Antisense oligonucleotides in inflammation research. In: Antisense Research and Applications, ST Crooke and B Lebleu (eds). CRC Press, Boca Raton, Florida, pp. 547-562.
• Bennett CF (1994). Inhibition of cell adhesion molecule expression with antisense oligonucleotides: Activity in-vitro and in-vivo. Clin. Chem. 40: 644-645.
• Bennett CF (1998). Antisense oligonucleotides: Is the glass half full or half empty? Biochem. Pharmacol. 55: 9-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bennett CF and Condon TP (1998). Use of antisense oligonucleotides to modify inflammatory processes. In: Antisense Research and Applications, ST Crooke (ed). Springer-Verlag, Berlin, pp. 371-393.
• Bennett CF, Kornbrust D., Henry S., Stecker K., Howard R., Cooper S., Dutson S., Hall W., and Jacoby HI (1997). An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther. 280: 988-1000.[Abstract/Free Full Text]
• Branda RF, Moore AL, Mathews L., McCormack JJ, and Zon G. (1993). Immune stimulation by an antisense oligomer complimentary to the rev gene of HIV-1. Biochem. Pharmacol. 45: 2037-2043.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Butler M., Stecker K., and Bennett CF (1997). Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. 77: 379-388.[Web of Science][Medline] [Order article via Infotrieve]
• Butler M., Stecker K., and Bennett CF (1997). Histological localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue. Nucleosides Nucleotides 16: 1761-1764.[CrossRef][Web of Science]
• Chiang MY, Chan H., Zounes MA, Freier SM, Lima WF, and Bennett CF (1991). Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266: 18162-18171.[Abstract/Free Full Text]
• Cossum PA, Troung L., Owens SR, Markham PM, Shea JP, and Crooke ST (1994). Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269: 89-94.[Abstract/Free Full Text]
• Crooke ST and Bennett CF (1996). Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol. 36: 107-129.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Geary RS, Leeds JM, Fitchett J., Burckin T., Troung L., Spainhour C., Creek M., and Levin AA (1997). Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. 25: 1272-1281.[Abstract/Free Full Text]
• Geary RS, Leeds JM, Henry SP, Monteith DM, and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12: 383-394.[Medline] [Order article via Infotrieve]
• Geary RS, Leeds JM, Henry SP, Monteith D., Truong L., Fitchett J., Burckin T., and Levin AA (1997). Pharmacokinetic properties of phosphorothioate oligonucleotides. In: Proceedings of the 12th International Roundtable—Nucleosides, Nucleotides, and their Biological Applications. September 15-19, 1997. in La Jolla, California.
• Geary RS, Leeds JM, Shanahan W., Gover J., Pribble J., Truong L., Fitchett J., Burckin R., Nicklin P., Philips J., and Levin AA (1996). Sequence Independent Plasma and Tissue Pharmacokinetics for 3 Antisense Phosphorothioate Oligonzccleotides: Mouse to Man. Plenum, Seattle, Washington.
• Glover JM. Leeds JM, Mant Tgk, Kisner DL, Zuckerman J., Levin AA, and Shanahan WR (1997). Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. 282: 1173-1180.[Abstract/Free Full Text]
• Henry SP, Bolte H., Auletta C., and Kornbrust DJ (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 120: 145-155.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Henry SP, Giclas PC, Leeds J. Pangburn M, Auletta C., Levin AA, and Kornbrust DJ (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J. Pharmacol. Exp. Ther. 281: 810-816.[Abstract/Free Full Text]
• Henry SP, Monteith D., and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicologic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12: 395-408.[Medline] [Order article via Infotrieve]
• Henry SP, Novotny W., Leeds J., Auletta C., and Kornbrust DJ (1997). Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 7: 503-510.[Web of Science][Medline] [Order article via Infotrieve]
• Henry SP, Taylor J., Midgley L., Levin AA, and Kornbrust DJ (1997). Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. 7: 473-481.[Web of Science][Medline] [Order article via Infotrieve]
• Klinman DM, Kyung Yae, Beaucage SL, Conover J., and Krieg AM (1996). CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon . Proc. Natl. Acad. Sci. USA 93: 2879-2883.[Abstract/Free Full Text]
• Krieg AM, Matson S., and Fisher E. (1996). Oligonucleotide modification determines the magnitude of B-cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 6: 133-139.[Web of Science][Medline] [Order article via Infotrieve]
• Krieg AM, Yi AK, Matson S., Waldschmidt TJ, Bishop GA, Teas-dale R., Koretzky GA, and Klinman DM (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.[CrossRef][Medline] [Order article via Infotrieve]
• Kumasaka T., Quinlan WM, Doyle NA, Condon TP, Bennett CF, Sligh J., Beaudet AL, and Doerschuk CM (1995). The role of ICAM-1 in E. coli endotoxin-induced pneumonia evaluated using ICAM-1 mutant mice or ICAM-1 anti-sense oligonucleotides. Am. Rev. Respir. Dis. 151: A456.
• Levin AA, Monteith DK, Leeds JM, Nicklin PL, Geary RS, Butler M., Templin MV, and Henry SP (1998). Toxicity of oligodeoxynucleotide therapeutic agents. In: Antisense Research and Applications, ST Crooke (ed). Springer-Verlag, Berlin, pp. 169-215.
• Monteith DK, Henry SP, Howard RB, Flournoy S., Levin AA, Bennett CF, and Crooke ST (1997). Immune stimulation——A class effect of phosphorothioate oligodeoxynucleotides in rodents. AntiCancer Drug Des. 12: 421-432.[Medline] [Order article via Infotrieve]
• Pisetsky DS and Reich CF (1994). Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 54: 101-107.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Quinlan WM, Doyle NA, Kumasaka T., Wancewicz E., Bennett CF, and Doerschuk CM (1994). The effect of ICAM-1 anti-sense oligonucleotides on the expression of ICAM-1 mRNA induced by E. coli endotoxin. Am. Rev. Respir. Dis. 150: A325.
• Stepkowski SM, Tu Y., Condon TP, and Bennett CF (1994). Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol. 153: 5336-5346.[Abstract]
• Stepkowski SM, Wang ME, Amante A., Kalinin D., Qu X., Blasdel T., Condon T., Kahan BD, and Bennett CF (1997). Antisense ICAM-1 oligonucleotides block allograft rejection in rats. Transplant. Proc. 29: 1285.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L., Rothlein RA, Mainolfi E., Tami JA, Bennett CF, Kisner DL, and Shanahan WR (1998). A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of steroid-dependent Crohn's disease. Gastroenerology 114: 1133-1142.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zhao Q., Temsamani J., Zhou RZ, and Agrawal S. (1997). Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 7: 495-502.[Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 27, No. 1, 95-100 (1999)
DOI: 10.1177/019262339902700117


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. B. Opalinska, A. Kalota, L. K. Gifford, P. Lu, K.-Y. Jen, P. I. Pradeepkumar, J. Barman, T. K. Kim, C. R. Swider, J. Chattopadhyaya, et al. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules Nucleic Acids Res., October 28, 2004; 32(19): 5791 - 5799. [Abstract] [Full Text] [PDF]

				M. K. Bijsterbosch, M. Manoharan, R. Dorland, R. van Veghel, E. A. L. Biessen, and T. J. C. van Berkel bis-Cholesteryl-Conjugated Phosphorothioate Oligodeoxynucleotides Are Highly Selectively Taken Up by the Liver J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 619 - 626. [Abstract] [Full Text] [PDF]

				B R Yacyshyn, W Y Chey, J Goff, B Salzberg, R Baerg, A L Buchman, J Tami, R Yu, E Gibiansky, and W R Shanahan Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease Gut, July 1, 2002; 51(1): 30 - 36. [Abstract] [Full Text] [PDF]

				L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach Catalytic Nucleic Acids: From Lab to Applications Pharmacol. Rev., September 1, 2000; 52(3): 325 - 348. [Abstract] [Full Text] [PDF]

				G. Pagnan, D. D. Stuart, F. Pastorino, L. Raffaghello, P. G. Montaldo, T. M. Allen, B. Calabretta, and M. Ponzoni Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects J Natl Cancer Inst, February 2, 2000; 92(3): 253 - 261. [Abstract] [Full Text] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Henry, S. P. Articles by Levin, A. A. Search for Related Content PubMed PubMed Citation Articles by Henry, S. P. Articles by Levin, A. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?